REG - BSF Enterprise PLC - Successful Cultivated Meat Test

BSF EnterpriseAnnouncement

30/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230530:nRSd8976Aa&default-theme=true

RNS Number : 8976A  BSF Enterprise PLC  30 May 2023

30 May 2023

 

BSF Enterprise PLC

("BSF" or the "Company")

 

Successful Cultivated Meat Test

BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the
owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues, is pleased to announce that it has successfully produced a
further two full-scale fillets of cultivated pork, as well as a cultivated
pork strip, which were presented at a technical event on Friday 25 May 2023.

 The cultivated pork fillets each measured 5 cm in diameter, 3 cm in height,
and circa 60 g in weight, making them similar in size to traditional 2-ounce
tenderloin steaks. This time, the Company had worked on increasing the
thickness of the fillet in comparison to the fillet produced in January this
year. In addition, the Company produced a cultivated pork strip, or 'noodle'
measuring circa 30 cm in length and 1 cm in diameter. The development of the
pork strip demonstrates the effectiveness of the Company's intellectual
property in being applied to produce meat in the future as a consumer-ready,
'pre-sliced' form for cooking purposes.

The cultivated meat products were produced using 3DBT's patented, serum-free
and animal-free cell booster City-Mix(TM), which eliminates the requirement of
conventional plant-based scaffolds, blends or fillers, as have been
universally adopted by the industry to date to ensure structural integrity of
cultivated meat products. 3DBT's products are therefore 100% structured meat,
produced without any animals suffering in its production.

The latest iteration of 100% meat products underwent testing, with data
collected and study participants invited to inspect the product in a raw and
cooked state. Study participants were limited to those persons who had a
 direct working relationship or involvement with the Company. The cultivated
meat fillets were then pan-fried and presented formally by a trained,
independent chef, while the meat strip was first cut in two portions, and
subsequently poached or pan-fried, in order to test an array of cooking
methods. The chef's involvement was key to demonstrating that the cultivated
meat could be handled and cooked in the same way as traditional meat, and the
results were very positive.

The Company is pleased to confirm that the 100% cultivated meat products were
very similar in appearance to conventional meat in their raw state, with
fibres clearly visible. The results from cutting and cooking the fillets were
also consistent with the previous results in terms of overall appearance,
aroma and searing/crisping. The Study participants that tasted the cultivated
meat provided very positive feedback in terms of its taste and texture.

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues,
commented: "We have gained a huge amount of valuable knowledge from testing
our products with a trained chef and we were reassured to observe that our
cultivated meat is able to be handled and cooked in the same way as
traditional meat products. Further, data collected from the study participants
indicated comparable meat qualities to traditional pork meat, which was very
pleasing and highly validating of our work. This gives us further confidence
as we continue our conversations with potential customers to licence out the
technologies demonstrated as well as building on the agreements already
secured."

Photographs of the cultivated meat products in raw and cooked states from the
Test Event can be found below:

 

The raw fillets and pork strip.

 

The cooked pork fillets.

 

A portion of the cooked pork strip.

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                         Via SEC Newgate below
 Che Connon - CEO & Executive Director

 Geoff Baker - Executive Director

 Shard Capital (Broker)
 Damon Heath                                0203 971 7000

 Isabella Pierre                            0207 1869 927

 SEC Newgate (Financial Communications)
 Bob Huxford                                020 3757 6882

 Elisabeth Cowell                           BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it has produced the
UK's first high quality lab-grown meat from its laboratory using its
technology.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
acquiring complementary businesses. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas, meat and
leather, and license out the IP to manufacturers, wholesalers and distributors
to help manufacture the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANSNALXDEFA